OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
OpenAI researcher Miles Wang is reportedly leaving the company to launch a startup focused on AI-driven drug discovery. The venture is seeking significant funding at a $2 billion valuation, reflecting a broader trend of investor interest in applying artificial intelligence to life sciences.
Why it matters
The move highlights the growing trend of top AI talent leaving major labs to pursue specialized, high-value applications in biotechnology and medicine.
Miles Wang , an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.
The report provides factual coverage of industry movements and funding trends without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in